What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Miguel A. Sanz mainly investigates Internal medicine, Surgery, Acute promyelocytic leukemia, Leukemia and Chemotherapy.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Immunology and Oncology.
In most of his Surgery studies, his work intersects topics such as International Prognostic Scoring System.
His Acute promyelocytic leukemia study also includes fields such as
- Mitoxantrone that intertwine with fields like Etoposide,
- Intensive care medicine which intersects with area such as MEDLINE, European LeukemiaNet, Clinical trial and Enasidenib.
His Leukemia research focuses on subjects like Myeloid leukemia, which are linked to Fms-Like Tyrosine Kinase 3, Acute leukemia and Myeloid.
Miguel A. Sanz has included themes like Incidence and Transplantation in his Chemotherapy study.
His most cited work include:
- International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes (3641 citations)
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2438 citations)
- Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia (2097 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Gastroenterology, Surgery, Oncology and Acute promyelocytic leukemia are his primary areas of study.
Chemotherapy, Leukemia, Transplantation, Myeloid leukemia and Cumulative incidence are among the areas of Internal medicine where the researcher is concentrating his efforts.
His Gastroenterology study integrates concerns from other disciplines, such as Univariate analysis, Incidence, Pathology and Graft-versus-host disease.
His Surgery study frequently draws connections between related disciplines such as Bone marrow.
His research in Oncology intersects with topics in Cytarabine, Hematology, Immunology and Myelodysplastic syndromes.
Miguel A. Sanz works mostly in the field of Acute promyelocytic leukemia, limiting it down to topics relating to Idarubicin and, in certain cases, Mitoxantrone.
He most often published in these fields:
- Internal medicine (69.56%)
- Gastroenterology (28.79%)
- Surgery (25.34%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (69.56%)
- Myeloid leukemia (22.87%)
- Oncology (26.45%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Myeloid leukemia, Oncology, Cumulative incidence and Acute promyelocytic leukemia.
Miguel A. Sanz combines topics linked to Gastroenterology with his work on Internal medicine.
His work deals with themes such as Newly diagnosed, Chemotherapy regimen and Refractory, which intersect with Myeloid leukemia.
Miguel A. Sanz combines subjects such as Cytarabine, Azacitidine, European LeukemiaNet and NPM1 with his study of Oncology.
His Cumulative incidence study combines topics from a wide range of disciplines, such as Umbilical Cord Blood Transplantation and Adult patients.
His Acute promyelocytic leukemia study combines topics in areas such as Arsenic trioxide, Cancer research, Obstetrics, Fetal viability and Leukemia.
Between 2018 and 2021, his most popular works were:
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet (134 citations)
- Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet (134 citations)
- Impact of NPM1/FLT3-ITD Genotypes Defined by the 2017 European LeukemiaNet in Patients With Acute Myeloid Leukemia (29 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Miguel A. Sanz focuses on Internal medicine, Myeloid leukemia, Acute promyelocytic leukemia, Oncology and Cumulative incidence.
His study involves Chemotherapy, Transplantation, Incidence, Hematopoietic stem cell transplantation and Retrospective cohort study, a branch of Internal medicine.
His work in the fields of Myeloid leukemia, such as European LeukemiaNet, overlaps with other areas such as Relevant information.
His Acute promyelocytic leukemia research is multidisciplinary, relying on both Cancer research, BAALC, Hyperfibrinolysis, Disease and Leukemia.
His work carried out in the field of Oncology brings together such families of science as Cytarabine, Idarubicin and Bone marrow.
Miguel A. Sanz works mostly in the field of Cumulative incidence, limiting it down to topics relating to Gastroenterology and, in certain cases, Stroke and Posterior reversible encephalopathy syndrome, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
